Work

A41 EO1001: A First-in-Class Irreversible Pan-ErbB Inhibitor with Excellent Brain Penetration

Year: 2020

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2019.12.125

Authors: W. Shen, J. Bacha, S. Kanekal, N. Sankar, W. ZhenZhong, Y. Yoshida, T. Ozawa, T. Yao, A. Parsa, J. Raizer, S. Cheng, A. Stegh, F. Giles, H. Pedersen, J. Sakaria, N. Butowski, C. James, D. Brown

Institutions: Kanion Pharmaceutical (China), University of California, San Francisco, Northwestern University, Mayo Clinic

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3003077004

Cites:

Cited by:

Related to: 10